Tosk Inc. Their mission is to improve outcomes for cancer patients by developing innovative drugs that enhance the safety and efficacy of existing therapies, as well as block the activity of cancer genes. Many current pharmaceutical products have limitations due to side effects, which can hinder their use and effectiveness.

However, Tosk employs proprietary methods to discover and develop new drugs that selectively block the adverse effects of existing treatments while maintaining their effectiveness. Notably, Tosk has recently developed a groundbreaking technology to discover drugs that block the activity of cancer genes. This technology is being used to target indications that were previously deemed undruggable.

Their initial focus is on the mutant KRAS gene, which drives up to 30% of all cancers. Driven by the aim to improve the quality of life and outcomes for patients, Tosk's drugs are designed to revolutionize cancer treatment regimens. These drugs are not only effective but also economically accessible, making them suitable for a global market.

Tosk has been featured in prominent media platforms such as American Health Journal and Innovations in Medicine, where Dr. Ian Ferrier and Brian Frenzel discuss the adverse side effects of cancer therapy and the exciting potential of Tosk's new drugs to mitigate them. For inquiries, you can contact Tosk through their telephone number: 408-245-6838, fax: 408-245-6808, or email: info@tosk.

com. Their headquarters is located at 2672 Bayshore Parkway, Suite 507, Mountain View, CA 94043, while their laboratory can be found at 725 San Aleso Avenue, Suite 4, Sunnyvale, CA 94085. Tosk - Empowering oncology patients with new solutions for a brighter future